Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
Source: Targeted Oncology, May 2024
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
The vibostolimab and pembrolizumab (Keytruda; MK-7684A) coformulation arm of the phase 3 KeyVibe-010 study (NCT05665595) investigating the agents as an adjuvant treatment in resected high-risk melanoma will be discontinued due to futility, according to Merck.
A higher discontinuation rate was observed in the coformulation arm vs the pembrolizumab monotherapy arm, making it unlikely that the study could achieve statistical significance for its primary end point of recurrence-free survival (RFS). The study will be unblinded and patients in the coformulation arm will have the option to receive pembrolizumab monotherapy.